Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd. based in New Jersey, has announced a strategic executive leadership re-organization and expansion of the company’s Executive Committee with the following changes effective July 1, 2022:
- Nate McCutcheon, currently Shionogi Inc.’s Chief Operating Officer, will be promoted to assume the role of President and Chief Executive Officer of Shionogi Inc.
- Tadashi Hara, currently Executive Vice President and Chief Financial Officer, will take on the newly created role of Executive Vice President and Chief Global Operations Officer.
- Joseph Spagnardi will continue his role as Executive Vice President, Legal and Compliance.
- Gianine Esposito will be promoted to Senior Vice President and Chief Human Resources Officer.
- Margaret Borys has recently joined the organization as Senior Vice President and Chief Commercial Officer.
- Masahiro Fujita will join Shionogi Inc. as Senior Vice President and Chief Financial Officer.
“As I return to Japan to lead Shionogi Pharma Co., Ltd, it was clear Nate McCutcheon was the right choice to take over the company’s helm given his professional experience and leadership abilities,” said Akira Kato, outgoing Shionogi Inc. President and CEO. “Both myself and the leadership in Japan have great confidence in his ability to advance Shionogi’s vision here in the U.S.”
“During my tenure with Akira we have helped Shionogi Inc. deliver a highly successful launch of Fetroja® (cefiderocol) and improved our financial position and efficiency significantly. I am very proud of what we have accomplished together,” said McCutcheon, newly-appointed President and CEO of Shionogi Inc. “I intend to maintain our current trajectory of success, but our efforts must now also turn to the tremendous opportunities we have in the future in terms of both organic and inorganic growth opportunities.”
“Today’s announcement of our newly formed executive team is an important step on our journey to make the U.S. business become an instrumental player within the network of Shionogi Group Companies. Since the release of the STS2030 medium-term business plan, we have taken significant strides to transform our organization so that we may bring the best possible medicines to the patients we serve. As the new President and CEO of Shionogi’s U.S. group company, I have full confidence that with the right team and the support from headquarters in Japan we can develop, acquire and commercialize a portfolio of products to transform our U.S. business.” McCutcheon said in closing
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!